A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases despite standard bisphosphonate (BP) therapy

✍ Scribed by M. Clemons; G. Dranitsaris; W.S. Ooi; D.E.C. Cole

• Book ID: 116319469
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 51 KB
• Volume: 38
• Category: Article
• ISSN: 8756-3282
• DOI: 10.1016/j.bone.2006.01.019